Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

PharmAthene Says FDA Places SparVax RPA Anthrax Vaccine Program On Clinical Hold

PharmAthene Inc. (PIP: Quote) has received notification from the U.S. Food and Drug Administration or FDA that its SparVax rPA anthrax vaccine program has been placed on clinical hold. The Agency indicated that the company would get a letter containing the details of the basis for the clinical hold within 30 days.

The company, during this period, would continue to provide the agency with analytical data from its recently produced GMP lot of material. The trial, which was expected to commence by the year end, has not enrolled any subjects to date and accordingly, there have been no adverse events reported.

Click here to receive FREE breaking news email alerts for PharmAthene and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.